Skip to main content
SpringerLink
Log in

Resistin levelispositively correlated with thrombotic complications in Southern Chinese metabolic syndrome patients

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: The metabolic syndrome (MetS) has been found to be closely related with thrombotic diseases. The mechanism, however, is far from elucidated. Aim: This study was designed to investigate the relationship between endogenous resistin and thrombosis mediating factors, as well as its potential effects on the gene expression of cardiovascular disease biomarkers. Methods: Ninety patients satisfied the MetS criteria, and 55 healthy subjects were recruited as part of a single-center clinical study. Plasma levels of resistin, tissue factor (TF), tissue factor pathway inhibitor (TFPI), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) were measured by enzyme-linked immunosorbent assays. The effect of resistin on the expression of cardiovascular disease biomarkers in human umbilical vein endothelial cells (HUVEC) was assayed by gene microarray. Results: 1) The average levels of resistin in MetS patients with or without acute myocardial or cerebral infarction were significantly higher than those of the controls. 2) The TF and TFPI increase was higher in MetS with infarction patients than in MetS patients. 3) In MetS with infarction patients, resistin was positively correlated with TF and PAI-1 (r=0.313, p=0.008; r=0.401, p=0.002, respectively). 4) In HUVEC, the microarray showed that apolipoprotein C-I, ACE, tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) and member 5 (CD40) genes expression were dramatically increased by resistin. Conclusion: In patients with MetS, resistin is strongly associated with hypercoagulative and hypofibrinolitic activities. Moreover, resistin may induce thrombotic complications via mediating the lipoprotein metabolism and stimulating inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008, 29: 777–822.

    Article  PubMed  CAS  Google Scholar 

  2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 365: 1415–28.

    Article  PubMed  CAS  Google Scholar 

  3. Bataille V, Perret B, Dallongeville J, et al. Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. A nested case-control study from the PRIME cohort. Diabetes Metab 2006, 32: 475–9.

    Article  PubMed  CAS  Google Scholar 

  4. Simons LA, Simons J, Friedlander Y, McCallum J. Does a diagnosis of the metabolic syndrome provide additional prediction of cardiovascular disease and total mortality in the elderly? The Dubbo Study. Med J Aust 2007, 186: 400–3.

    Google Scholar 

  5. Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007, 28: 857–64.

    Article  PubMed  Google Scholar 

  6. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006, 69: 76–85.

    Article  PubMed  CAS  Google Scholar 

  7. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001, 409: 307–12.

    Article  PubMed  CAS  Google Scholar 

  8. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007, 156: 279–84.

    Article  PubMed  CAS  Google Scholar 

  9. Osawa H, Ochi M, Tabara Y, et al. Serum resistin is positively correlated with the accumulation of metablic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf) 2008, 69: 74–80.

    Article  CAS  Google Scholar 

  10. Takata Y, Osawa H, Kurata M, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008, 51: 534–9.

    Article  PubMed  CAS  Google Scholar 

  11. Ohmori R, Momiyama Y, Kato R, et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46: 379–80.

    Article  PubMed  Google Scholar 

  12. Pischon T, Bamberger CM, Kratzsch J, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13: 1764–71.

    Article  PubMed  CAS  Google Scholar 

  13. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111: 932–9.

    Article  PubMed  CAS  Google Scholar 

  14. Iqbal N, Seshadri P, Stern L, et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 2005, 9: 161–5.

    PubMed  CAS  Google Scholar 

  15. Filippidis G, Liakopoulos V, Mertens PR, et al. Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif 2005, 23: 421–8.

    Article  PubMed  CAS  Google Scholar 

  16. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987, 235: 1348–52.

    Article  PubMed  CAS  Google Scholar 

  17. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991, 66: 6–15.

    PubMed  CAS  Google Scholar 

  18. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 1984, 108: 150–8.

    Article  PubMed  CAS  Google Scholar 

  19. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366: 1059–62.

    Article  PubMed  Google Scholar 

  20. Jin H, Qiu WB, Mei YF, et al. Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor down-regulation via suppression of nuclear factor-kappa B in endothelial cells. Asian J Androl 2009,11: 266–71.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  21. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110: 1245–50.

    Article  PubMed  Google Scholar 

  22. Hong Y, Jin X, Mo J, et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality—results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med 2007, 262: 113–22.

    Article  PubMed  CAS  Google Scholar 

  23. Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism—a manifestation of the metabolic syndrome. Haematologica 2007, 92: 374–80.

    Article  PubMed  CAS  Google Scholar 

  24. Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008, 93: 3165–72.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  25. Qi Q, Wang J, Li H, et al. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol 2008, 159: 585–93.

    Article  PubMed  CAS  Google Scholar 

  26. Lubos E, Messow CM, Schnabel R, et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007, 193: 121–8.

    Article  PubMed  CAS  Google Scholar 

  27. Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008, 93: 2647–53.

    Article  PubMed  CAS  Google Scholar 

  28. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002, 106: 2442–7.

    Article  PubMed  CAS  Google Scholar 

  29. DelGiudice LA, White GA. The role of tissue factor and tissue factor pathway inhibitor in health and disease states. J Vet Emerg Crit Care (San Antonio) 2009, 19: 23–9.

    Article  Google Scholar 

  30. Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000, 20: 1362–73.

    Article  PubMed  CAS  Google Scholar 

  31. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009, 35: 468–77.

    Article  PubMed  CAS  Google Scholar 

  32. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism 2008, 57: 494–501.

    Article  PubMed  CAS  Google Scholar 

  33. de Haan W, Out R, Berbée JF, et al. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo. Biochem Biophys Res Commun 2008, 377: 1294–8.

    Article  PubMed  CAS  Google Scholar 

  34. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009, 54: 669–77.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of ICU, the First Affiliated Hospital of Shantou University Medical College, Shantou, China

    W. Q. Fang

  2. Department of Cardiology, the First Affiliated Hospital of Shantou University Medical College, Shantou, China

    Q. Zhang & H. Jin MD

  3. Shantou University Medical College, Shantou, China

    Y. B. Peng, M. Chen, X. P. Lin, J. H. Wu & C. H. Cai

  4. Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin, China

    Y. F. Mei MD

Authors
  1. W. Q. Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Q. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. B. Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X. P. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. H. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. H. Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. F. Mei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Jin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Y. F. Mei MD or H. Jin MD.

Additional information

These authors contributed equally to the paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fang, W.Q., Zhang, Q., Peng, Y.B. et al. Resistin levelispositively correlated with thrombotic complications in Southern Chinese metabolic syndrome patients. J Endocrinol Invest 34, e36–e42 (2011). https://doi.org/10.1007/BF03347059

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347059

Key-words

Search

Navigation